Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
Generic TDF/FTC reached the highest monthly share of users among all medications from December ... Trends in Oral and Injectable HIV Preexposure Prophylaxis Prescriptions in the US, 2013-2023 ...
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...
HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...
The increasing incidence of sexually transmitted bacterial infections (STIs) is a major public health problem worldwide.
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Natal, alarming gaps between scientific advancements and community behaviour persist. This article explores the critical need ...
Did you know with a Digital Subscription to Yorkshire Evening Post, you can get unlimited access ... detect infections and ...
(HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and ... Generic TDF/FTC reached the highest monthly share of users among all medications from December 2021 to December ...